MONTE ROSA THERAPEUTICS - TO CO-FUND PHASE 3 DEVELOPMENT OF MRT-6160 AND SHARE 30% OF PROFITS AND LOSSES IN U.S.

Reuters · 2d ago

Please log in to view news